Open house Arzneimittelrabattverträge Ertugliflozin, ATC A10BK04
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Ertugliflozin, ATC A10BK04
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No guaranteed volume or minimum purchase; participation may not be commercially viable.
Monthly submission deadline for quick start: documents must be in by 3rd of month to start next month.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Supply of Ertugliflozin (ATC A10BK04) under non-exclusive discount agreements
- Non-exclusive, open-to-all model; no competition or selection
Show full summary
This is an open-house (non-procurement) model for non-exclusive drug discount agreements for Ertugliflozin (ATC A10BK04) with AOK Bayern. All eligible pharmaceutical companies can join on identical terms. Contracts run from June 2026 to May 2028, with possible conclusion anytime until April 2028. No estimated value is provided. Only a signed declaration of reliability is required. The procedure is not subject to procurement law.
Risks
No guaranteed volume or minimum purchase; participation may not be commercially viable.
Monthly submission deadline for quick start: documents must be in by 3rd of month to start next month.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies (pharmazeutische Unternehmen) are eligible
Certifications
- Documents must be in German or accompanied by a certified German translation
Administrative
- Submit signed contract, completed annex 'Festlegung der vertragsgegenständlichen Arzneimittel', and signed declaration of reliability
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open house Arzneimittelrabattverträge Ertugliflozin, ATC A10BK04
Non-exclusive discount agreements for the active substance Ertugliflozin (ATC A10BK04). All eligible pharmaceutical companies may join. Contracts are identical and not individually negotiable. Performance in Bavaria, Germany.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Show original TED data
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 257130-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
No guaranteed volume or minimum purchase; participation may not be commercially viable.
Monthly submission deadline for quick start: documents must be in by 3rd of month to start next month.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications